|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||55.89 - 56.29|
|52 Week Range||48.56 - 59.57|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.40%|
CLS Investments' Rusty Vanneman offers ETF picks for investors with a globally balanced portfolio to enhance potential returns.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? In December 2017, Teva Pharmaceutical Industries (TEVA) laid out a detailed restructuring plan for the company to turn around its ailing business due to a number of challenges it’s facing.
In August 2017, the FDA approved Teva Pharmaceutical's (TEVA) Austedo for the treatment of adult individuals with tardive dyskinesia.
Value stocks in the United States are scuffling against broader benchmarks and growth stocks. While ex-US developed markets value stocks are also trailing relevant benchmarks, the value factor is performing ...